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ABSTRACT 36 
Docosahexaenoic acid (DHA) is the main long chain omega-3 polyunsaturated fatty acids in 37 
the brain and accounts for 30% to 40% of fatty acids in the grey matter of the human cortex. 38 
Although the influence of DHA on memory function is widely researched, its association 39 
with brain volumes is under investigated and its association with spatial navigation is 40 
virtually unknown. This is despite the fact that spatial navigation deficits are a new cognitive 41 
fingerprint for symptomatic and asymptomatic Alzheimer’s disease (AD). We investigated 42 
the relationship between DHA levels and the major structural and cognitive markers of 43 
preclinical AD, namely hippocampal volume, entorhinal volume, and spatial navigation 44 
ability. Fifty-three cognitively normal adults underwent volumetric magnetic resonance 45 
imaging, measurements of serum DHA (including serum lysophosphatidylcholine DHA 46 
(LPC DHA)) and APOE ε4 genotyping. Relative regional brain volumes were calculated and 47 
linear regression models were fitted to examine DHA associations with brain volume. APOE 48 
genotype modulated serum DHA associations with entorhinal cortex volume and 49 
hippocampal volume. Linear models showed that greater serum DHA was associated with 50 
increased entorhinal cortex volume, but not hippocampal volume, in APOΕ ε4 non-carriers. 51 
APOE also interacted with serum LPC DHA to predict hippocampal volume. After testing 52 
interactions between DHA and APOE ε4 on brain volume, we investigated whether DHA and 53 
APOE interact to predict spatial navigation performance on a novel virtual reality diagnostic 54 
test for AD in an independent population of APOE genotyped adults (n = 46). Crucially, the 55 
APOE genotype modulated DHA associations with spatial navigation performance, showing 56 
that DHA was inversely associated with path integration in APOE ε4 carriers only. 57 
Interventions aiming to increase DHA status to protect against cognitive decline must 58 
consider APOE ε4 carrier status, and focus on higher doses of supplementary DHA to ensure 59 
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Abbreviations 70 
AD= Alzheimer’s disease 71 
APOE= Apolipoprotein E 72 
DHA= Docosahexaenoic 73 
DNA= Deoxyribonucleic acid 74 
BMI=body mass index 75 
HDL=high-density lipoprotein 76 
BDNF=Brain-derived neurotrophic factor 77 
LPC= Lysophosphatidylcholine 78 
TG=triglyceride 79 
FAs=fatty acids 80 
CVLT= California Verbal Learning Test 81 
MOCA= Montreal Cognitive Assessment 82 
ACE=Addenbrookes cognitive examination 83 
ROCF=Rey–Osterrieth Complex Figure 84 
FAs=fatty acids 85 
CI= confidence interval 86 
GLM=General linear model 87 
MRI=magnetic resonance imaging 88 
PCR= Polymerase chain reaction 89 
TIV= total intracranial volume 90 
ω-3 PUFA= omega-three polyunsaturated fatty acids 91 
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INTRODUCTION 104 
Alzheimer’s disease (AD) is the most common form of dementia with increasing world-wide 105 
prevalence. In the absence of any licensed drugs to treat or reverse cognitive decline 106 
associated with AD, dietary behaviours which prevent or slow brain atrophy in the entorhinal 107 
cortex and the hippocampus hold tremendous potential (Larson et al., 2013; Lewis et al., 108 
2014; Vauzour et al., 2017). Higher long chain omega-3 polyunsaturated fatty acids (LC ω-3 109 
PUFA) have been linked to better memory function and lower the risk of developing AD 110 
(Lim et al., 2006; He et al., 2009; Yassine et al., 2016; Ammann et al., 2017). However, the 111 
effect of LC ω-3 PUFA on spatial navigation is virtually unknown, despite evidence that 112 
spatial disorientation may appear in conjunction with, or prior to, episodic memory loss in 113 
AD (Tu et al., 2015; Lester et al., 2017; Coughlan et al., 2018). Therefore, elucidating the 114 
effect of LC ω-3 PUFA on spatial navigation and on its associated brain regions is of high 115 
interest.  116 
 117 
Docosahexaenoic acid (DHA), the main ω-3 PUFA in the brain which accounts for 30% to 118 
40% of fatty acids in the grey matter of the human cortex and is especially enriched at the 119 
synapse (Lacombe et al., 2018). Disturbances in brain DHA metabolism have been 120 
implicated in a host of neurodegenerative diseases, particularly AD. This may be because the 121 
beneficial properties of DHA appear to be concentrated in the hippocampus (Pottala et al., 122 
2014) (particularly the CA1 subfield (He et al., 2009)) and the entorhinal cortex (Arsenault et 123 
al., 2011; Yassine et al., 2016). Major animal studies show long-term DHA supplementation 124 
in mice with preclinical AD reverses amyloid accumulation, protects against neuronal loss 125 
associated with AD pathology, and critically, improves overall navigation performance 126 
(Oksman M, Iivonen H, 2006; He et al., 2009). Conversely, reduced ω-3 PUFA levels has 127 
been shown to impair hippocampal plasticity and reduce navigation function (Lim et al., 128 
2005; Fedorova et al., 2007), suggesting that DHA may be beneficial in prevention AD. 129 
 130 
Despite brain DHA levels being 10-fold higher in specific brain regions relative to most body 131 
tissues, and strong evidence for neurocognitive benefits proposed by animal models, the 132 
neuronal benefits in humans are less consistent. In the Framingham Heart Study, serum 133 
phosphatidylcholine DHA levels were associated with a 47% reduction in risk of dementia 134 
over 9 years of follow-up (Schaefer et al., 2006), but in a similar dementia-free Dutch cohort, 135 
dietary DHA intake was not associated with relative risk for AD (Devore et al., 2009). 136 
Moreover, the AD Cooperative Study reported no effect of DHA supplementation (18 137 
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months) on composite measures of cognition in adults with mild to moderate AD 138 
(Tomaszewski et al., 2020), but a subset of the Ageing Brain Study led by the University of 139 
Southern California shows higher serum DHA levels are associated with lower cerebral 140 
amyloidosis and preservation of entorhinal and hippocampal volumes (Yassine et al., 2016). 141 
 142 
The unexamined role of the apolipoprotein (APOE) genotype is also a major factor behind 143 
the mixed results from human studies (Chouinard-Watkins and Plourde, 2014; Zamroziewicz 144 
et al., 2015; Yassine, 2017). The APOE ε4 isoform is the most important prevalent genetic 145 
determinant of AD risk  (Corder et al., 1993) and disrupts blood-brain barrier function in the 146 
hippocampus and wider medial temporal lobe, compared to the other APOE isoforms (ε2/ε3) 147 
(Montagne et al., 2020). This then suggests that a faulty blood brain barrier system in APOE 148 
ε4 carriers may impair the transport of circulating DHA to the brain, which has been shown 149 
in older APOE ε4 mice (Vandal et al., 2014). Therefore, we hypothesized that the APOE 150 
genotype would modulate circulating blood DHA associations with brain volume and spatial 151 
navigation. We further hypothesized that higher DHA levels would be positively related to 152 
preserved brain entorhinal and hippocampal volume, as well as spatial navigation 153 
performance in ε4 non-carriers only. We expected that these associations would be non-154 
significant or negative in ε4 carriers. 155 
 156 
METHODS 157 
This is a cross-sectional study examining the effect of APOE ε4 on DHA associations with 158 
entorhinal cortex volume, hippocampal volume and spatial navigation performance across 159 
two non-demented cohorts. 160 
 161 
Setting 162 
Non-demented adults were drawn from the Cognitive Ageing, Nutrition and Neurogenesis 163 
study and formed cohort one (Irvine et al., 2018). Recruitment and screening began in 2015 164 
and all neuroimaging data was collected by March 2017 across two data collection sites; the 165 
Swinburne University of Technology (Melbourne, Australia) and the University of East 166 
Anglia (UEA, Norwich, United Kingdom). At screening, cognitive status was pre-classified 167 
with a modified telephone interview for cognitive status and Montreal Cognitive Assessment 168 
tool (Nasreddine, 2005). Participants were invited for baseline neuropsychological testing 169 
and a baseline MRI scan. Blood samples were taken immediately following cognitive testing. 170 
 171 
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To investigate DHA associations with spatial navigation, we recruited a second cohort.  172 
Between February 2017 and June 2017, participants from this cohort were recruited to 173 
participate in a research study at Norwich Medical School, UEA and invited for spatial 174 
navigation and neuropsychological testing. Blood samples were taken immediately following 175 
testing.  176 
 177 
Standard protocol approvals, registrations, and consents 178 
Cohort one was acquired from the Cognitive Ageing, Nutrition and Neurogenesis study 179 
(ClinicalTrials.gov NCT02525198) and obtained ethical approval from the Swinburne 180 
University Human Research Ethics Committee (Study identifier SHR Project 2015-208) for 181 
the Swinburne University of Technology site and the National Research Ethics Service 182 
Committee for the University of East Anglia site (Study identifier 14/EE/0189). Ethical 183 
approval for the second navigation study (cohort two) was obtained from the Faculty of 184 
Medicine and Health Sciences Ethics Committee at UEA, UK, (Reference FMH/2016/2017–185 
11). All participants from both studies provided informed signed consent before participating. 186 
 187 
Participants 188 
Participants from cohort one were a mean age of 64.7 (SD 7.6) years. Participants from 189 
cohort two were 61.3 (SD 5.6) years. Exclusion criteria for both samples included diagnosis 190 
of mild cognitive impairment, clinical dementia, significant neurologic/ psychiatric disorder, 191 
MRI evidence of brain damage, previous vascular disorders including infarction or stroke and 192 
history of alcohol or drug dependency within the last 2 years. In addition, homozygous APOE 193 
ε4 carriers (2% of the population) and APOE ε2 carriers (13% of the UK population) were 194 
excluded, due to their low population prevalence. Included were (1) APOE ε3ε4 allele 195 
carriers, who are at a 3-fold increased risk of developing AD and represent 23% of the 196 
population (moderate risk, high prevalence), and (2) age-gender matched ε3ε3 carriers, who 197 
represent the population wild-type genotype (60% of the population). (Liu et al., 2013) All 198 
participants had normal or corrected-to-normal vision. 199 
 200 
APOE genotyping 201 
In both cohorts, DNA was extracted and used for APOE genotyping. In cohort one, DNA was 202 
extracted from the buffy coat layer (containing the white cell layer) of each participant blood 203 
sample, and placed in a ethylenediaminetetraacetic acid tube (BD Biosciences, San Diego, 204 
CA, USA). In cohort two, DNA was extracted from a Darcon tip buccal swab LE11 5RG; 205 
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Fisher Scientific), using a commercial DNA extraction kit (Qiagen, Hildenberg, Germany). 206 
DHA from both samples underwent PCR amplification and plate read analysis using Applied 207 
Biosystems 7500 Fast Real-Time PCR System (TN23 4FD; Thermo Fisher Scientific) to 208 
determine participants’ APOE genotype status. Further details for each cohort are detailed 209 
elsewhere (Irvine et al., 2018; Coughlan et al., 2019). 210 
 211 
DHA measurements 212 
Cohort one 213 
Free/non-esterified fatty acid DHA and lysophosphatidylcholine (LPC) DHA was measured 214 
from a fasted blood samples, and 20μl of serum was utilised for analysis. Ten microlitres of 215 
high purity water and 40μl of MS-grade methanol were added, followed by a 2 min vortex 216 
mix to precipitate proteins. 200 μl of methyl t-butyl ether was added, and the samples were 217 
mixed via vortex at room temperature for 1 h. After the addition of 50 μl of high purity water, 218 
a final sample mixing was performed before centrifugation at 10000 g for 10 min. The upper, 219 
lipid-containing, methyl t-butyl ether phase was then extracted and analysed by liquid 220 
chromatography-mass spectrometry. The analytical method is detailed elsewhere (Whiley et 221 
al., 2012). The single molecule integrated peak areas under the exact mass chromatographs 222 
of LPC-DHA were obtained by using Skyline by setting up an integration parameter file 223 
using its mass charge ration (m/z) and retention time (510.35 m/z and 3.0 minutes) (MacLean 224 
et al., 2010; Peng and Ahrends, 2016). LPC DHA is the most important lipid pool to deliver 225 
DHA to the brain via the blood–brain barrier (Sugasini et al., 2017, 2019, 2020).  226 
 227 
Cohort two 228 
Erythrocyte DHA was measured from a non-fasted blood samples collected using a single 229 
drop of whole blood obtained via a finger prick collection kit (Faculty of Natural Sciences 230 
Institute of Aquaculture, University of Stirling). Blood samples were immobilised on a 231 
specially made card and sent to the University of Stirling (Stirling, UK) for analysis. Please 232 
see Carboni et al., (2019) for a full description of the Blood Spot PUFA analysis used to 233 
derive fatty acid erythrocyte concentrations (Carboni et al., 2019). In cohort 2, fasting status 234 
was not needed as DHA was measured in the erythrocyte phospholipid fraction, which is 235 
reflective or long term (up to 3 months) fatty acid intake and little influenced by recent DHA 236 
or overall fatty acid intake.     237 
 238 
Volumetric MRI 239 
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Structural T1-weighted images were obtained using either a three-dimensional fast spoiled 240 
gradient echo brain volume imaging sequence in the sagittal orientation, repetition time (TR)/ 241 
echo time (TE)/inversion time (TI) = 7,040/2.612/900 ms, 0.9 mm isotropic resolution, field 242 
of view (FOV) = 230 × 230 mm, number of excitations (NEX) = 0.5, or a using a three-243 
dimensional magnetization prepared rapid gradient echo (sequence, TR/TE/TI = 244 
1,900/2.32/900 ms, 0.9 mm isotropic resolution, FOV = 230 × 230 mm, generalized 245 
autocalibrating partial parallel acquisition, acceleration factor of 2 depending on site. Full 246 
acquisition details are documented elsewhere (Irvine et al., 2018). 247 
 248 
Cortical surface reconstruction and segmentation was performed with FreeSurfer image 249 
analysis suite (version 6.0.0) (http://freesurfer.net/). The automised processing stream 250 
includes motion correction, removal of non-brain tissue, automated Talairach transformation, 251 
intensity correction, volumetric segmentation, cortical surface reconstruction, and 252 
parcellation. Quality checks included skull stripping and pial surface errors, intensity 253 
normalisation, white matter segmentation errors and were conducted on Freeview after 254 
processing and before statistical analysis. Entorhinal volume was derived from the Desikan-255 
Killiany atlas (Desikan et al., 2006). Hippocampal volumes were derived based on an atlas 256 
derived from combining high-resolution ex vivo data and in vivo data. 257 
 258 
Cognitive assessments 259 
In cohort one, intact cognitive status was pre-determined. Details on the cognitive assessment 260 
are outlined elsewhere (Irvine et al., 2018). Participants were assessed on the California 261 
Verbal Learning Task, the Montreal Cognitive Assessment and Digital Span to test for 262 
cognitive differences between APOE ε4 carriers and non-carriers (Elwood, 1995; Nasreddine, 263 
2005). In cohort two, the Addenbrooke's cognitive evaluation and the Rey-Osterrieth 264 
complex figure test were available to confirm the sample was free of cognitive impairment 265 
and that there were no differences between APOΕ ε4 carrier and non-carriers. Spatial 266 
navigation performance was measured using the Virtual Supermarket Test adopted by the 267 
European Prevention of Alzheimer’s Dementia Consortium to assess the efficacy of 268 
potentially AD modifying treatments. Details for the spatial navigation task can be found 269 
elsewhere (Tu et al., 2015, 2017; Coughlan et al., 2020). 270 
 271 
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Statistical analysis 272 
The data were analysed using RStudio (version 1.0.153). Linear regression models were 273 
specified with entorhinal and hippocampal volume as outcome variables, and DHA and 274 
APOE genotype as predictors (including an interaction term). Models were adjusted for age, 275 
sex, education, test centre and total estimated intracranial volume. Additional dietary 276 
variables such as total intake of green vegetables and fruit did not contribute to overall model 277 
fit based on the bayesian information criterion criteria and were not retained in the final 278 
models. In the spatial navigation dataset, adjustments for test centre and intracranial volume 279 
were dropped as volumetric MRI was not the outcome variable and data collection took place 280 
at one site only. Standardized residuals were extracted and plotted against fitted values to 281 
examine underlining assumption of normal distribution and heteroscedasticity. In the case of 282 
significant APOE x DHA interactions, post-hoc linear models were specified with APOΕ ε4 283 
carriers (ε3ε4) and non-carriers (ε3ε3) separately. All statistical tests are two-tailed: P < 0.05. 284 
Partial eta squared (np
2) was used as a measure of effect sizes and was derived from 285 
lmSupport package in R (https://cran.r-project.org/web/packages/lmSupport). np
2 is the ratio 286 
of variance associated with an effect plus that effect and its associated error variance (np
2 = 287 
SSeffect / SSeffect + SSerror).  288 
 289 
Data availability 290 
The authors have documented all data, methods, and materials used to conduct the research in 291 
this article and agree to share anonymized data by request from the first author or 292 
corresponding author. 293 
 294 
RESULTS 295 
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Table 1. Participant characteristics in cohort one. Data are presented as mean (SD) for 306 
normally distributed data or median for non-normal distributions. The two groups were 307 
compared by an independent sample t test. Serum free DHA is measured as total DHA in 308 
serum, in the free/non-esterified fatty acid form. 309 
 Mean (SD)    
  APOE genotype   
Characteristic     





Age, (y) 64.2 (7.2) 65.0 (7.9)  64.0 (6.9) .65 
Sex (male/female) 21/33 7/9 15/22  
Education, (y) 14.2 (2.9) 14.5 (2.8) 14.1 (3.0) .63 
     
Serum free DHA (ug/mL) 1.23 (.64) 1.22 (.59) 1.23 (.66) .96 
Serum LPC DHA (ug/mL)   2.81 (1.39) 2.23 (1.49) 2.10 (1.26) .43 
     
Blood pressure     
  Systolic (mm Hg) 133 (17) 121 (23) 126 (14) .61 
  Diastolic (mm Hg) 77 (8.8) 72 (7.3) 75 (7.8) .10 
BMI (kg/m2)  26.9 (4.0) 27.1 (4.9) 26.9 (3.8) .87 
 









Serum cholesterol (mmol/l)     
  Total 5.11 (0.9) 5.04 (1.2) 5.12 (0.8) .82 
  HDL 1.51 (4.5) 1.39 (5.2) 1.44 (3.9) .81 
Serum TG (mmol/l) 1.21 (0.5) 1.59 (0.6) 1.47 (.4) .48 
Serum BDNF (pg/mL) 18958 (4676) 19359 (4702) 18144 (4589) .13 
     
Brain volume     
Hippocampal volume (ratio of 
total intracranial volume) 
.0045 (.00038) .0044 (.00046) .0045 (.00035) .36 
Entorhinal volume (ratio of total 
intracranial volume) 
.0024 (.00031) .0023 (.00025) .0024 (.00033) .29 
Cognition     
CVLT (delayed free recall) 10.99 (2.3) 10.43 (2.7) 11.16 (2.3) .28 
MOCA (delayed recall) 3.11 (1.3) 3.07 (1.2) 3.24 (1.4) .68 
MOCA (total) 27.87 (1.7) 27.73 (1.7) 27.93 (1.8) .72 
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Table 2. Participant characteristics in cohort two.  318 
Data are presented as mean (SD) for normally distributed data or median (IQR) for non-319 
normal distributions. The two groups were compared by an independent sample t-test.  320 
 Mean (SD)    
  APOE genotype   





Socio-demographic     
 Age, (y) 61.30 (5.6) 60.82 (5.7) 61.75 (5.7) .58 
 Sex (male/female) 15/31 4/18 11/13  
 Education, (y) 14.4 (5.4) 14.5 (2.9) 14.4 (3.6) .72 
     
Erythrocyte DHA (% of total FA) 2.64 (.71) 2.76 (.73) 2.52 (.62) .25 
 
Blood pressure (missing=3) 
    
  Not medicated 36 18 18 .61 
  Medicated 7 3 1 .10 
 
Cholesterol (missing=3) 
    
  Not medicated 39 19  20  .55 
  Medicated 4 2 2 .81 
 
Cognition 













ROCF     
  Copy 32 (2.8) 32 (2.8) 32 (2.9) .55 
  Recall 19 (5.8) 17 (5.2) 20 (6.1) .08 
     
 321 
Serum DHA associations with entorhinal and hippocampal volume 322 
Serum free DHA (in the free/non-esterified fatty acid form) predicted right (t= 2.15, p=0.03, 323 
np
2=0.09) and left (t=2.33, p= 0.02, np
2=0.11; Figure 1 A-B) entorhinal volume. There was a 324 
significant interaction between serum free DHA and APOE genotype status on the left 325 
entorhinal volume (t=-2.20, p=0.03, np
2=0.10), with a trend evident for the right side (t=-2.00, 326 
p=0.05, np
2= 0.09). Independent linear models for APOE ε3ε3 and APOE ε3ε4 carrier groups 327 
revealed a positive association between serum free DHA levels and entorhinal volume in 328 
ε3ε3 carriers only (for both hemispheres: left t=2.67, p=0.01; right t=2.28, p=0.02). The DHA 329 
× APOE interaction was not significant for hippocampal volume, although there was a trend 330 
toward significance (right hemisphere: t=1.72, p=0.09; see Figure 1 C-D).  331 
Serum lysophosphatidylcholine associations with entorhinal and hippocampal volume 332 
LPC data was available from one of the two research sites in cohort one (n=30). LPC DHA 333 
predicted right hippocampal volume (t=2.31, p=0.03, np2=0.22), with a significant LPC DHA 334 
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× APOE interaction (t= -2.24, p=0.03, np2= 0.19) and a positive and negative association 335 
trend was evident in APOE ε3ε3 carriers and APOE ε3ε4 carrier’s receptivity, but was not 336 
significant. Against predictions, there was no main effect of LPC DHA and entorhinal 337 
volume, suggesting the serum free DHA is associated with entorhinal cortex, but the LPC 338 
fraction is more strongly associated to the hippocampus in this sample.  339 
APOE effects on brain volume                         340 
We also investigated if the APOE genotype effects entorhinal cortex and hippocampus 341 
volume by removing the DHA predictor from the model which may have pulled variance 342 
from the APOE genotype. No main effects of APOE were found on entorhinal cortex volume 343 
(left: t=-1.71 p=0.09; right: t=-0.47, p=0.64) or hippocampus volume (left: t=-0.76, p=0.44; 344 
right t=-1.44, p=0.15), adjusting for age, sex, education, test site and total intracranial 345 
volume. See supplementary Table 1 for a summary of the DHA effects on brain volume. 346 
DHA associations with spatial navigation 347 
In cohort two, we examined associations between erythrocyte DHA (the available blood 348 
DHA measure), and navigation processes known to be vulnerable to early AD. Specifically, 349 
we tested DHA associations with boundary-based place memory and egocentric path 350 
integration (n=46). Both processes tap into grid-cell mechanisms in the entorhinal cortex, 351 
which translate information to place cells in the hippocampus (Shine et al., 2019). There was 352 
a main effect of DHA on boundary-based place memory, which was marginally significant 353 
(t=-2.017, p=0.058). APOE genotype modulated DHA associations with egocentric path 354 
integration (t=-2.06, p=0.04), with DHA inversely associated with path integration (b=-.834, 355 
t=2.69, p=0.01) in ε3ε4, but not in ε3ε3 (b=.31, t=1.487, p=.153; see Figure 2). These 356 
findings imply that higher circulating DHA predicts worse path integration performance in 357 
the ε4 carrier group only. See supplementary Table 1 for a summary of effects on spatial 358 
navigation. 359 
 360 
DHA associations with brain regions beyond the medial temporal lobe 361 
Finally, we investigated if the APOE genotype and DHA interact to predict volumes of other 362 
AD vulnerable brain regions in the human spatial navigation network, namely the precuneus 363 
and posterior cingulate cortex. No significant interactions (or main effects of serum free 364 
DHA or LPC DHA) on brain volume were found (see supplementary Table 2) suggesting that 365 
the effects of DHA are concentrated in the entorhinal cortex and hippocampus. 366 
 367 
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DISCUSSION 368 
Our findings imply that the APOE ε4 allele alters associations between circulating DHA and 369 
volumes of the entorhinal cortex and hippocampus in non-dementia adults, almost a decade 370 
before the expected age of AD onset. Circulating serum DHA predicted greater entorhinal 371 
cortex volume, with a significant interaction between DHA and APOE genotype. As 372 
predicted, the positive association between DHA and entorhinal volume was evident in 373 
APOE ε4 non-carriers only. Our results also show that in APOE ε4 carriers, serum DHA was 374 
inversely correlated with path integration (path integration is a process used in spatial 375 
navigation). We propose that the impaired blood brain barrier function and reduced DHA 376 
transport to the entorhinal cortex and hippocampus as an explanation for this. Unexpectedly, 377 
serum DHA was not positively associated with path integration in APOE ε4 non-carriers, 378 
which could be due to the small-moderate sample size. Together, the results imply that 379 
disrupted DHA absorption from the blood to the brain may exist in the genetically-at-risk of 380 
AD adult population, and may mediate navigation deficits seen in adults genetically-at-risk or 381 
preclinical AD cohorts. 382 
 383 
Serum DHA predicted greater entorhinal volume in non-demented older adults, consistent 384 
with previous findings for a beneficial influence of circulating DHA (from serum or 385 
erythrocytes) on brain health. (Tan et al., 2012; Yassine et al., 2016; Ammann et al., 2017; 386 
Yassine, 2017; Zhang et al., 2017) The entorhinal cortex has one of the highest 387 
concentrations of lipoprotein receptors in the brain (due to the presence of APOE receptors 388 
LRP1) which are involved in DHA tissue delivery to neurons and clearance of amyloid βeta 389 
(Lane-Donovan et al., 2014), potentially explaining why DHA was associated with both these 390 
regions and not the precuneus cortex or the posterior cingulate cortex. However, the 391 
beneficial association of DHA with brain volume was exclusive to ε4 non-carriers in our 392 
study, consistent with two similar observational studies (Barberger-Gateau et al., 2007; 393 
Whalley et al., 2008). Daiello and colleagues previously showed that DHA supplementation 394 
predicted the preservation of the cerebral cortex gray matter and the hippocampus in ε4 non-395 
carriers only, (Daiello et al., 2015)  pointing to a neuroprotective effect of DHA that is at 396 
least partially exclusive to adults who do not bare the risk of the ε4 allele.  397 
The spatial navigation study from cohort two supported this theory. Among adults who did 398 
bare the risk of the ε4 allele, circulating DHA predicted worse navigation proficiency. To the 399 
best of our knowledge, this is the first report of a significant association between circulating 400 
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DHA and AD vulnerable spatial navigation performance. Path integration, a sub-process 401 
involved in navigation ability, involves the capacity to use self-motion cues (or movements 402 
cues) to update and learn spatial location information in relation to a start location (Etienne 403 
and Jeffery, 2004) and is particularly vulnerable to early AD pathophysiology (Howett et al., 404 
2019). This process relies crucially on the structural integrity of the entorhinal cortex and 405 
hippocampus that were notably associated with serum DHA here (Hasselmo, 2008; Banino et 406 
al., 2018). Almost a decade ago, He et al., demonstrated that increased brain DHA (via 407 
supplementation) significantly increased number of proliferating hippocampal cells 408 
and subsequently improved spatial learning performance in the Morris water maze (He et al., 409 
2009). In our APOE ε4 group, increased circulating DHA was associated with decreased 410 
navigation performance, supporting evidence that APOE ε4 disrupts blood-brain barrier 411 
function predicting cognitive decline (Chouinard-Watkins and Plourde, 2014; Yassine et al., 412 
2017; Montagne et al., 2020). 413 
A landmark paper by Montague and colleagues provides important insights into a deficit 414 
blood brain barrier transport system in APOΕ ε4 carriers. The authors report that APOE ε4 415 
carriers present with blood–brain barrier breakdown in the hippocampus and medial temporal 416 
lobes leading to cognitive decline. Lower brain uptake of DHA in older APOE ε4 mice has 417 
also been shown to limit the accumulation of DHA in cerebral tissues, providing a potential 418 
mechanistic explanation for the inverse association between DHA and spatial navigation in 419 
APOE ε4 shown here (Vandal et al., 2014). Other explanations for APOE related changes in 420 
DHA metabolism beside blood brain barrier function include i) ε4 carrier status results in 421 
physiological dysregulation that is associated with both lower brain DHA uptake (and 422 
resultant higher blood levels) and deleterious changes to medial temporal lobe physiology 423 
and function, or ii) there is greater DHA uptake in adipose tissue for storage in APOE ε4 424 
carriers with less available for brain tissue absorption via the blood brain barrier. Other 425 
potential explanations for the increase in free serum DHA among APOE ε4 may be that this 426 
reflects greater activation of phospholipase A2, which liberates esterified DHA from 427 
phospholipid (Gungor et al., 2012), suggesting that the increase in DHA is a biomarker of 428 
another process such enhanced vascular inflammation, as opposed to being directly linked to 429 
AD pathology. All mechanisms warrant further investigation.  430 
We examine the effect of APOE ε4 on the association between circulating DHA, entorhinal 431 
cortex, hippocampal volume and spatial navigation, which is uncommon as most studies 432 
focus on memory or other cognitive functions. Strengths of our study include a rigours DHA 433 
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analysis, including the serum LPC-DHA lipid fraction, a comprehensive phenotyping of 434 
participants, adjusting for confounders, as well as the inclusion of a virtual reality spatial 435 
navigation diagnostic test of AD. The findings produced in this study have the following 436 
limitations however: 1) Although a unified model with an interaction term is the optimum 437 
method to test effect modification, an important limitation is that more statistical power is 438 
required than for association testing, and thus false-negative results may be seen in smaller 439 
samples. There were fewer ε4 carriers in cohort one, compared to cohort two, which may 440 
account for why in in APOE ε4 carriers we found a significant inverse association between 441 
DHA and navigation performance, but a null association between DHA and entorhinal-442 
hippocampal brain volume. 2) Likewise, the small sample sizes do not preclude the 443 
possibility that our findings could be observed by chance. These results will nevertheless play 444 
an important role in hypothesis-generating for future cross-sectional studies and RCTs. 3) 445 
Non-fasted blood samples from cohort two mean that if participant had a meal that was very 446 
high in DHA prior to testing that this may influence their DHA measurement, compared to a 447 
fasted sample. 4) While spatial navigation crucially relies on the integrity and function of the 448 
entorhinal cortex and the hippocampus, we cannot directly relate the participants across 449 
cohort one and two. Future studies should thus examine if entorhinal and hippocampal brain 450 
volume directly mediates the relationships between DHA and spatial navigation. 5) Given the 451 
observational nature of the study, and that DHA (fish intake) is a component of an overall 452 
healthy diet (Weichselbaum et al., 2013), we cannot preclude the possibility of confounding 453 
residual and that DHA-brain phenotype associations were attributable to other dietary factors. 454 
To address this potential, confound, we tested various other dietary factors such as vegetable 455 
and fruit intake, which did not contribute to a significant amount of variance in the outcome 456 
variables of interest and therefore, where not retained in the downstream analysis. Given that 457 
brain and serum DHA has been previously linked to a range of neuro-protective processes in 458 
animal and human models, it is unlikely that the association are due to other diet derived 459 
bioactives.  460 
 461 
In conclusion, we provide novel evidence that APOE genotype modifies DHA associations 462 
with brain volume and spatial navigation ability, typically affected in the first stages of AD. 463 
Future studies should examine the mechanisms behind the APOE genotype modulating effect 464 
of DHA, brain volume and cognitive function associations, particularly blood brain barrier 465 
integrity. Future positron emission tomography studies needed to measure rates of DHA 466 
incorporation from plasma into the brain (Yassine et al., 2017), which would confirm if DHA 467 
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uptake to the brain is reduced in older APOE ε4 carriers, leading to spatial navigation 468 
impairment. As over 50% of APOE ε4 carriers do not develop clinical AD, longitudinal 469 
studies are clearly required to determine whether APOE ε4, coupled with disrupted DHA 470 
absorption to the brain, has diagnostic utility, and can predict conversion to clinical AD with 471 
a high degree of accuracy (Henderson et al., 1995). Another important line of research will 472 
be to examine a therapeutic target in APOE ε4 carriers to mitigate the negative effect on the 473 
allele on brain health. For example, it is possible that cyclophilin A inhibitors might suppress 474 
the pathway that is believed to cause blood brain barrier breakdown in the cerebral blood 475 
vessels of APOE ε4 carriers, and thereby may slow spatial navigation impairment and other 476 
cognitive functions that rely on blood supply to the brain. (Stanciu et al., 2019; Montagne et 477 
al., 2020). Moreover, supplementation trials should focus on higher doses of DHA to ensure 478 
adequate brain delivery in APOE ε4 carriers, as previous suggested (Arellanes et al., 2020). 479 
Finally, understanding whether different blood lipid fractions differentially supply DHA to 480 
the entorhinal cortex and hippocampus in humans may refine DHA intervention approaches 481 
in treatment trials for AD.  482 
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FIGURE LEGENDS 671 
Figure 1. Serum DHA associations with entorhinal and hippocampal brain volume from 672 
cohort one (n=53). 673 
A-B There was a significant interaction between APOE genotype and DHA on left entorhinal 674 
volume. In ε3ε3 carriers, serum free DHA was significantly associated with right entorhinal 675 
volume and explained 20% of volume variability (R2 = .20, p=.005). Serum free DHA 676 
explained 8% of the variability in the left entorhinal volume (R2 = .75, p=100). C-D No 677 
interaction between serum free DHA levels and APOE genotype on hippocampal volume was 678 
found, and no main effects of serum fre/ DHA on hippocampal volume were found, although 679 
there was a trend toward significance. Confidence intervals represented by dotted curve lines 680 
are shown in for associations in the ε3ε3 groups.  681 
Figure 2. DHA association with spatial navigation performance from cohort two (n=46). 682 
There was a significant interaction between APOE genotype and DHA on left egocentric path 683 
integration. Total DHA in erythrocytes was inversely related to egocentric path integration in 684 
cognitively intact APOE ε3ε4 carriers only. No significant association was found in the ε3ε3 685 
carrier group. 686 
 
 
 
